SK Biopharmaceuticals Co (XKRX:326030) Ending Cash Position : ₩289,508 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co Ending Cash Position?

SK Biopharmaceuticals Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ₩289,508 Mil.

SK Biopharmaceuticals Co's quarterly Ending Cash Position declined from Sep. 2023 (₩271,392 Mil) to Dec. 2023 (₩239,700 Mil) but then increased from Dec. 2023 (₩239,700 Mil) to Mar. 2024 (₩289,508 Mil).

SK Biopharmaceuticals Co's annual Ending Cash Position declined from Dec. 2021 (₩225,922 Mil) to Dec. 2022 (₩104,060 Mil) but then increased from Dec. 2022 (₩104,060 Mil) to Dec. 2023 (₩239,700 Mil).

SK Biopharmaceuticals Co Ending Cash Position Historical Data

The historical data trend for SK Biopharmaceuticals Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Biopharmaceuticals Co Ending Cash Position Chart

SK Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

51,140.95

59,333.24

225,922.28

104,059.70

239,700.04

SK Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															103,577.08	106,443.05	271,392.41	239,700.04	289,507.71

SK Biopharmaceuticals Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SK Biopharmaceuticals Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	104059.701	+	135640.341
	=	239,700

SK Biopharmaceuticals Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	239700.043	+	49807.665
	=	289,508

SK Biopharmaceuticals Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of SK Biopharmaceuticals Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Biopharmaceuticals Co (XKRX:326030) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbp.com

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

SK Biopharmaceuticals Co (XKRX:326030) Headlines

No Headlines